Fennec (NASDAQ: FENC) CFO exercises 14,184 options, adds shares

Rhea-AI Filing Summary

Fennec Pharmaceuticals chief financial officer Robert Andrade reported exercising stock options and acquiring common shares of the company. On January 7, 2026, he exercised 14,184 stock options at an exercise price of $2.45 per share, which resulted in acquiring 14,184 common shares. After this transaction, he beneficially owned 191,100 common shares directly and held 836,567 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrade Robert

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NC 27709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	01/07/2026		M		14,184	A	$2.45	191,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options(1)	$2.45	01/07/2026		M			14,184	07/05/2016	07/05/2026	Options	14,184	$2.45	836,567	D

Explanation of Responses:

1. Shares acquired through the exercise of an option contract with strike price of $2.45 and an expiration date of July 5, 2026.

	/s/ Robert Andrade	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did FENC CFO Robert Andrade report?

Robert Andrade, the chief financial officer of Fennec Pharmaceuticals, reported exercising 14,184 stock options at $2.45 per share and acquiring 14,184 common shares on January 7, 2026.

Did the FENC CFO sell or acquire shares in this Form 4 filing?

In this Form 4, the FENC CFO acquired shares. He exercised 14,184 stock options, which resulted in acquiring 14,184 common shares; no sale of common shares is reported.

How many Fennec Pharmaceuticals common shares does the CFO own after the transaction?

Following the reported transaction, the CFO beneficially owned 191,100 common shares of Fennec Pharmaceuticals directly.

What is the status of the CFO’s stock options after this FENC Form 4 transaction?

After exercising 14,184 stock options at $2.45 per share, the CFO directly held 836,567 stock options in total, with the exercised options originally expiring on July 5, 2026.

What does transaction code "M" mean in the FENC Form 4 for the CFO?

The transaction code "M" indicates an exercise or conversion of derivative securities, here reflecting the exercise of stock options into 14,184 common shares.

Who is the insider involved in this FENC Form 4 filing and what is their role?

The insider is Robert Andrade, who serves as chief financial officer of Fennec Pharmaceuticals Inc. and is identified as an officer but not a director or 10% owner.